Pharmaceutical major Zydus has launched a new biosimilar for cancer treatment, reinforcing its commitment to improving access to advanced therapies at more affordable prices. The launch comes amid rising demand for cost-effective oncology solutions as cancer incidence continues to grow and treatment expenses escalate. By adding another biosimilar to its portfolio, Zydus aims to address both clinical needs and economic pressures faced by patients and healthcare systems.